Thousand Oaks Biologics at CPHI Frankfurt 2025
Thousand Oaks Biologics, a leading Asia-based CRDMO, announced its participation in CPHI Frankfurt 2025, held from October 28-30.
The company will showcase its integrated ADC CRDMO solutions and media innovation for industrialization at Booth 4.1H54 in the Bioproduction Zone.
Thousand Oaks Biologics is a trusted partner in the global biopharmaceutical ecosystem, driven by AI and innovative drug discovery technologies.
Antibody-drug conjugates (ADCs) are a key driver of China's innovative drug globalization.
Author's summary: Thousand Oaks Biologics participates in CPHI Frankfurt 2025.
More News
- Trump keeps flirting with the idea of a third term. That would be unconstitutional
- Wizz Air Revives $580 Pass and Tests Business Class
- How excess rains and poor wastewater management send microplastics into city lakes
- We need a new Turing test to assess AI’s real-world knowledge
- Hong Kong Tennis Open: last China players exit as top seed Bencic progresses
- Hong Kong Tennis Open: last China players exit as top seed Bencic progresses
- Hong Kong Tennis Open: last China players exit as top seed Bencic progresses
- Anti-VEGF innovations in retinal disease: From molecules to medicine | Ophthalmology Times - Clinical Insights for Eye Specialists
- Dutch election: D66 and PVV neck and neck with smallest difference ever
- ‘Meek diplomacy’: is Asean doing enough to end the Myanmar conflict?